Skip to main content

Table 2 Meta-analysis of CYP2E1 rs2031920 C/T polymorphism and SCC risk

From: Analysis of the role of rs2031920 and rs3813867 polymorphisms within the cytochrome P450 2E1 gene in the risk of squamous cell carcinoma

Comparisons

Group

Number (study)

OR

95% CI

P (association)

Allele model (allele T vs. allele C)

All

18

0.84

0.67–1.06

0.144

 

Asian

11

0.80

0.61–1.05

0.106

 

Caucasian

4

1.04

0.46–2.37

0.929

 

HNSCC

6

0.99

0.62–1.59

0.971

 

ESCC

6

0.67

0.48–0.95

0.025

 

LSCC

5

0.94

0.67–1.32

0.722

 

PB

15

0.83

0.68–1.02

0.076

 

HB

3

1.00

0.38–2.58

0.994

 

Y

14

0.92

0.75–1.13

0.449

 

N

4

0.60

0.37–0.99

0.048

Carrier model (carrier T vs. carrier C)

All

18

0.83

0.69–1.01

0.064

 

Asian

11

0.80

0.60–1.00

0.053

 

Caucasian

4

0.99

0.49–1.99

0.982

 

HNSCC

6

0.96

0.65–1.43

0.849

 

ESCC

6

0.70

0.53–0.93

0.014

 

LSCC

5

0.92

0.68–1.25

0.602

 

PB

15

0.83

0.71–0.98

0.027

 

HB

3

0.98

0.44–2.16

0.955

 

Y

14

0.91

0.78–1.06

0.236

 

N

4

0.62

0.42–0.92

0.018

Homozygote model (TT vs. CC)

All

15

0.87

0.65–1.15

0.324

 

Asian

11

0.83

0.62–1.12

0.324

 

Caucasian

3

2.18

0.66–7.19

0.202

 

HNSCC

4

1.35

0.69–2.62

0.379

 

ESCC

5

0.65

0.44–0.96

0.029

 

LSCC

5

1.27

0.69–2.33

0.440

 

PB

12

0.85

0.62–1.17

0.316

 

HB

3

0.94

0.49–1.79

0.847

 

Y

11

0.90

0.65–1.24

0.522

 

N

4

0.76

0.42–1.38

0.371

Heterozygote model (CT vs. CC)

All

18

0.74

0.54–1.02

0.067

 

Asian

11

0.68

0.45–1.02

0.064

 

Caucasian

4

0.93

0.51–1.71

0.825

 

HNSCC

6

0.92

0.66–1.28

0.617

 

ESCC

6

0.56

0.32–0.97

0.040

 

LSCC

5

0.82

0.45–1.47

0.503

 

PB

15

0.73

0.56–0.96

0.024

 

HB

3

0.85

0.23–3.17

0.804

 

Y

14

0.85

0.69–1.05

0.139

 

N

4

0.48

0.23–1.01

0.054

Dominant model (CT + TT vs. CC)

All

21

0.81

0.60–1.11

0.189

 

Asian

12

0.80

0.54–1.19

0.263

 

Caucasian

6

0.85

0.42–1.71

0.644

 

HNSCC

8

0.95

0.56–1.62

0.844

 

ESCC

6

0.58

0.35–0.96

0.035

 

LSCC

5

0.87

0.53–1.44

0.591

 

PB

18

0.81

0.61–1.07

0.138

 

HB

3

0.89

0.24–3.33

0.864

 

Y

15

0.90

0.72–1.12

0.345

 

N

4

0.50

0.25–0.99

0.046

Recessive model (TT vs. CC + CT)

All

16

1.21

0.80–1.83

0.362

 

Asian

12

1.20

0.78–1.84

0.402

 

Caucasian

3

2.11

0.23–19.71

0.512

 

HNSCC

5

1.88

0.91–3.90

0.089

 

ESCC

5

0.91

0.47–1.74

0.770

 

LSCC

5

1.47

0.81–2.69

0.206

 

PB

13

1.18

0.72–1.94

0.514

 

HB

3

1.24

0.66–2.34

0.497

 

Y

11

1.05

0.65–1.71

0.829

 

N

4

1.26

0.70–2.28

0.438

  1. OR odds ratio, CI confidence interval, HNSCC head and neck squamous cell carcinoma, ESCC esophageal squamous cell carcinoma, LSCC lung squamous cell carcinoma, PB population-based control, HB hospital-based control, Y P value of hardy–weinberg equilibrium > 0.05, N P value of hardy–weinberg equilibrium > 0.05
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us